A

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Computational Scientist - Mass Spectrometry

Quantitative Biology & BiostatisticsConfirmed live in the last 24 hours
Full-timeSouth San Francisco, CA, USANo salary listedIn-person

About the Job

Requirements

  • Deep experience in computational liquid chromatography–tandem mass spectrometry (LC-MS/MS), particularly untargeted metabolomics and complex mixture analysis.
  • Strong programming skills and a track record of building reliable scientific software.
  • A strong foundation in analytical chemistry, ionization, fragmentation, chromatography, and the physics of mass spectrometry.
  • Experience developing algorithms or extending tools such as MZmine or OpenMS to solve challenging analytical problems.
  • Rigorous judgment about data quality, measurement uncertainty, and the evidence needed to support a molecular identification or biological conclusion.
  • Python, NumPy, SciPy, pandas, SQL, and reproducible scientific software development; C++ is a plus.
  • LC-MS/MS processing, including feature detection, peak integration, alignment, deconvolution, isotope and adduct annotation, and quality control.
  • Untargeted metabolomics, spectral library matching, fragmentation prediction, molecular identification, and quantitative analysis.
  • Tools and formats such as MZmine, OpenMS, MS-DIAL, SIRIUS, GNPS, and mzML.
  • Cheminformatics and molecular representations, including RDKit, SMILES, molecular fingerprints, and structure similarity.
  • LLM APIs, agent tool development, scientific data retrieval, and automated analysis workflows.
  • Agent evaluation, trace analysis, and benchmarks with experimentally verified answers and uncertainty-aware scoring.
  • Statistical methods for calibration, batch correction, differential abundance, and integration with imaging, transcriptomics, and proteomics.

Responsibilities

  • Build computational tools and AI agents for LC-MS/MS feature detection, peak alignment, molecular identification, quantification, and quality control.
  • Develop agents that predict molecular fragmentation and identify structures by combining mass spectra, chromatography, UV, and NMR evidence.
  • Solve complex mixture analysis problems, including overlapping peaks, background interference, matrix effects, and uncertain compound identities.
  • Build reliable workflows for relative and absolute quantification, accounting for calibration, measurement uncertainty, and compound-dependent signal responses.
  • Combine analytical chemistry expertise with agents to investigate drug metabolism, identify reactive metabolites, and interpret drug-induced metabolic changes.
  • Work with experimental scientists to generate datasets and verified reference measurements that reveal where computational methods and agents succeed or fail.
  • Turn experiments into benchmarks and reinforcement learning environments that teach frontier models increasingly complex chemical reasoning and analysis.
  • Integrate metabolomics with imaging, transcriptomics, and proteomics to uncover mechanisms of drug toxicity and guide further experiments.

Desired Qualifications

  • Excitement about building and using AI agents to interpret experimental data, test chemical hypotheses, and automate scientific analysis.
  • Curiosity and ownership, with a desire to work closely with experimental scientists and see methods improve real experiments.
  • C++ programming experience.

About the Company

Axiom Bio

AI-driven hepatotoxicity prediction for drugs

Axiom Bio provides an AI-driven platform for predictive toxicology that helps drug researchers identify potential liver toxicity early in development. The platform uses a large proprietary dataset—over 115,000 small molecules screened on primary human liver cells with imaging and biochemical readouts, plus PK and clinical data—to predict drug-induced liver injury and related toxicity pathways from a molecule’s structure. It differentiates itself through its large human-toxicity dataset and by offering mechanistic insights (such as mitochondrial toxicity, ER stress, and ROS) at a low per-molecule cost. The goal is to speed up safe drug development by de-risking preclinical pipelines and reducing reliance on animal testing.

Company size
11-50
Company stage
Seed
Total funding
$15M
Headquarters
San Francisco, CA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Axiom Bio

See more jobs